Crossmark

Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health professionals

Crossref DOI link: https://doi.org/10.1186/s13023-022-02551-y

Published Online: 2022-10-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pascoal, C.

Ferreira, I.

Teixeira, C.

Almeida, E.

Slade, A.

Brasil, S.

Francisco, R.

Ligezka, A. N.

Morava, E.

Plotkin, H.

Jaeken, J.

Videira, P. A.

Barros, L.

dos Reis Ferreira, V. https://orcid.org/0000-0002-0696-2169
License Information

Text and Data Mining valid from 2022-10-29

Version of Record valid from 2022-10-29
More Information

Article History

Received: 28 June 2022

Accepted: 11 October 2022

First Online: 29 October 2022

Declarations

:

: Participants voluntarily agreed to participate in the study after informed consent.

: Not applicable.

: Horacio Plotkin declares a financial interest as an employee for Glycomine, Inc, which might be considered as a competing interest. The other authors declare that they have no known competing interests.

Document is current

Any future updates will be listed below